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Pigmented macules appearing in sun-protected sites 
of psoriatic patients treated chronically with oral meth-
oxsalen photochemotherapy (PUV A) have been charac-
terized as a lentiginous proliferation of relatively large, 
sometimes cytologically atypical, melanocytes (i.e., 
PUV A lentigines). In 1380 psoriatic adults followed 
prospectively, PUV A lentigines of any degree (slight, 
moderate, or extensive) were noted on the buttocks of 
53% of patients at the most recent examination (an 
average of 5.7 years after starting PUVA). The fre-
quency of moderate or extensive buttock lentigines at 
the most recent examination was positively associated 
with a greater number of PUV A treatments, an older 
age at starting PUV A, and male sex, and negatively 
associated with skin types V and VI. Moderate or exten-
sive buttock lentigines were present in 17% of 693 
patients who had not had PUVA for 1-2 years or longer. 
According to a regression analysis, the persistence of 
buttock lentigines was related in greatest measure to 
the total number of PUV A treatments received and was 
relatively independent of the time interval from the last 
PUV A treatment to the most recent examination or to 
"other" UV radiation therapy (predominantly UVB) re-
ceived after PUV A was discontinued. Until the long-
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term course of PUV A lentigines is known, individuals 
who develop "fixed" pigmented lesions while on PUV A 
should be monitored continually for melanocytic dyspla-
sias, including melanoma. 
Chronic t herapeutic doses of methoxsalen photochemoth er-
apy (PUV A) in humans may induce c ircumscribed pigmented 
macules on all treatment s ites (Fig 1). Recen t investigations 
have demonstrated t hat t hese PUV A-induced pigmented m ac-
ules are characterized by a lentiginous proliferation of relat ively 
hypertrop hic, som etimes cytologically atypical, melanocytes 
[1,2] (Fig 2) . We refer to these m acules as PUVA len t igines. 
Usin g treatment histo ries a nd physical examinations of p so-
riatic patients enrolled in t he PUVA Follow-Up Study [3,4], 
we report t he risk factors associated wit h t he development of 
PUV A len t igines. 
METHODS 
S tudy Population 
T hirteen hundred and eighty patients with psoriasis who began 
PUVA in 16 university medical centers prior to October 1, 1976, we re 
enrolled in t he PUVA Follow-Up Study [3,4]. As of September 1, 1982, 
1269 of t hese patients had had at least one physical examination 2 or 
more years a fte r start ing PUVA. The most recent of t hese examinations 
occurred an average of 5.7 years after t he first PUVA t reatment . 
Incomplete information did not exceed 5% for any single parameter 
ana lyzed. 
Of the 1380 patients , 94 died before September 1, 1982. One study 
center, which included 187 patients, did not collect comparable physical 
examination data prior to start ing PUV A; patients from this center 
were excluded from analyses requiring pretreatment examination data. 
Cha racte ristics of t he patients from t his one cente r, as well as the 
design for t he Follow-Up Study, a re deta iled elsewhere [3,4]. 
Prior to start ing PUV A and every year thereafter, t he prominence 
of lentigines [5-8] and ove rall actinic damage (wrinkling, scaling, and 
telangiectasia) on t he dorsa of the hands were qualitatively assessed as 
none, slight, moderate, or extensive. Because of t he ra rity of lent igines 
on the buttocks, no quantitation in th is location was made prior to 
starting PUV A. Once lent igines and actinic damage in sun-protected 
sites were noted during exa minations 2 years afte r the t rial began , a 
semiquantitative estimate of t hese findings on the buttocks was sub-
sequently incorporated in to the annual examinat ions. 
Skin type was assessed according to an individual's historic burning 
and tanning response to sunlight [3]. The MISAR system of data 
management [9] was used to store and process data. 
Statist1:cal Analysis 
For variables t hat were significantly correlated with buttock len-
t igines at t he most recent examination (an average of 5. 7 years afte r 
the first PUV A treatment), a multiple regression analysis was used to 
assess t he re lative contribution of each variable to t he observed vari -
ance in t he prevalence and severity of buttock lent igines. Variables 
examined included t he tota l number of t reatments received before the 
most recent examination, age at start ing PUVA, sex, and duration 
between the last PUV A t reatment and the most recent examination. 
For analyses of variance and correlation or regression, the assessment 
of buttock lent igines was converted to a numerical score, i.e., 0, 1, 2, 
and 3, representing none, slight, moderate, and extensive, respectively. 
We performed an addit ional regression analysis which related t he 
logari t hm of the total number of PUV A t reatments (rather t han t he 
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FIG 1. PUVA-induced lentigines on all treatment-exposed surfaces, 
including t he relatively "sun-protected" hips and buttocks. Inset, 
Higher magnification of buttock lentigines (scale in millimeters) . 
total number of treatments alone) to t he buttock lentigines score, 
because of significant residuals observed when the actua l buttock 
lenti gines score was compared to that predicted for patients with large 
numbers of PUV A treatments. Differences in mean buttock lentigines 
scores were assessed usi ng the Student t-test when there were 2 groups, 
the F-test when there were 3 or more groups, and the Pearson product 
moment correlation (r) when the variable was continuous. Differences 
in proportions were assessed using two-by-two tables and the Chi -
square or one-tailed Fisher's exact test [10] . 
FIG 2. Buttock lentigo (A) and adjacent nonlesional buttock skin 
(B) in a patient receiving ch ron ic PUVA, and light-protected buttock 
skin (LPS) (C) in an individua l not receiving UVR. Melanocytes 
(arrows) along club-shaped epidermal rete ridges in the PUVA lentigo 
(A) are more numerous, slightly more hypert rophic, more dendritic, 
and more dopa -reactive than melanocytes in adjacent nonlesiona l 
buttock skin (B), and LPS (C). Compared to LPS (C), melanocytes in 
PUVA -exposed nonlesional buttock sk in (B) are also more numerous 
and more dendritic. (Hematoxyli n and eosin stain; 6 l'm-thick dopa 
section; x 400; scale bars equal 10 I'm.) 




Lentigines of any degree (slight, moderate, or extensive) (Fig 
1) were present on the buttocks in 45% (497 /1112) and 53% 
(676/1269) of patients an average of 3 and 5. 7 years, respec-
tively, after starting PUVA (p < 0.001) . Buttock lentigines 
graded as moderate or extensive were present in 15% (170/ 
1112) and 24% (299/1269) of patients an average of 3 and 5.7 
years, respectively, after starting PUVA (p < 0.001). 
Number of Treatments 
Patients who had received 2: 100 PUV A treatments by the 
most recent examination were significantly more likely to have 
moderate or extensive buttock lentigines than patients who 
had received < 100 PUV A treatments (Table I). In an analysis 
of variance, the mean buttock lentigines score at the most 
recent examination showed a stepwise increase based on the 
total number of treatments received (F = 18.93, 2-sided p < 
0.01) . The mean buttock lentigines score at the most recent 
examination was correlated with the logarithm of the total 
number of PUVA treatments received (r = 0.27, F = 99.73, 
one-sided p < 0.0001) (Spearman rank correlation = 0.292). 
The frequency of moderate or extensive buttock lentigines at 
the most recent examination was positively associated with 
moderate or extensive actinic damage on the buttocks and dorsa 
of the hands, and moderate or extensive lentigines on the dorsa 
of the hands (Table I). 
Age and Sex 
Patients who started PUV A at age 35 years or older were 
more likely to have moderate or extensive buttock lentigines at 
the most recent examination than patients who started PUV A 
at age< 35 years: 230/863 (27 %) vs 71/426 (17%) (p < 0.001) . 
More males than females had moderate or extensive buttock 
lentigines at the most recent examination: 211/829 (25%) vs 
90/460 (20%) (p < 0.02). 
A multiple regression equation that related the 3 individual 
variables significantly associated with the frequency and sever-
ity of buttock lentigines (total PUV A treatments, age at start-
ing PUV A, and sex) indicated that 80% of the observed variance 
was accounted for by the logarithm of the total treatments 
received, 17% by age at starting PUVA, and 4% by sex (r = 
0.30, p < 0.01). 
Skin Type 
Patients with skin types V and VI were significantly less 
likely to have moderate or extensive buttock lentigines at the 
most recent examination (Table 1). When skin types I-IV were 
analyzed separately, there were no significant differences in the 
proportions of patients with moderate or extensive buttock 
lentigines according to individual skin type (p > 0.2). Although 
there was no significant association between skin type and total 
PUV A treatments received at participating centers, there was 
a significant association between skin type and average PUVA 
dose (Table II). 
Persistence of Buttock Lentigines 
Patients who had received PUV A within 1 year prior to their 
most recent examination were more likely to have moderate or 
extensive buttock lentigines (178/588, 30%) than patients who 
had not received PUVA for 1- 2 years (35/154, 23 %) or > 2 
years (85/539, 16%) (p < 0.001). These differences in the 
severity of buttock lentigines at the most recent examination 
were ascribed to a greater total number of PUV A treatments 
(mean ± SD) received by patients who had had PUVA within 
1 year prior to their most recent examination (161 ± 87) , 
compared to those who had not had PUVA for 1- 2 years (127 
± 73) and > 2 years (72 ± 54) (F = 223.8, 2-sided p < 0.01). A 
multiple regression that related the buttock lentigines score at 
the most recent examination to (a) the log total number of 
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TABLE I. Frequency of PUVA -induced buttoch lentigines at the most 
recent examination," related to selected patient characteristics 
Patient 
characteristics 
PUV A treatments received 
<100 
~100 
Actinic damage, buttocks 
None or slight 
Moderate or extensive 
Actinic damage, dorsal hands 
None or slight 
Moderate or extensive 
Lentigines, dorsal hands 
None or slight 











234/ 1196 (20%) 
67/93 (72%) 
183/1031 (18%) 
118/ 258 (46%) 
118/ 962 (12%) 
183/ 327 (56%) 
13/83 (16%) 
78/ 293 (27%) 
168/ 689 (24 %) 







"Most recent examination conducted: a mean of 5.7 years after 
starting PUV A. 
1
' Skin types V and VI vs I- IV. 
TABLE II. Relationship of shin type, total PUVA treatments, and 










t reatments• (N) 
126 ± 97' (84) 
122 ± 83 (300) 
117 ± 81 (706) 
121 ± 84 (169) 
150 ± 92 (19) 
96 ± 93 (22) 
F = 1.1, 2-sided p > 0.05 
Average PUV A doseb 
in J oules/ cm2 (N) 
8.0 ± 5.1< (57) 
10.5 ± 5.0 (225) 
13.1 ± 5.9 (604) 
14.8 ± 6.3 (126) 
13.0 ± 5.7 (17) 
18.6 ± 8.6 (18) 
F = 21.4, 2-sided p < 0.01 
• Not counting treatments received outside participating centers. 
b Since initial "clearing phase" of treatment. 
' Mean± SD. 
PUV A treatments received, (b) the time interval in weeks from 
the most recent examination to the most recent PUVA treat-
ment, and (c) a history of "other" UVR therapy (mainly UVB) 
in the year prior to the most recent examination, indicated that 
95 % of the observed variance was accounted for by the log total 
number of PUV A treatments, 4% by the time interval from the 
most recent examination to the most recent PUV A treatment, 
and 2% to "other" UVR therapy received in the year prior to 
the most recent examination (r = 0.30) (p < 0.01). 
DISCUSSION 
PUV A has been associated with the induction of "poikilo-
dermatous" and "nevus spilus-like" macular pigmentation [11-
14] and circumscribed pigmented macules [1,2,15- 19] grossly 
similar to ultraviolet radiation (UVR)-induced "freckles" 
[20,21] and lentigines [5- 8]. While there may be some disa-
greement about the histologic interpretation of PUV A-induced 
pigmented macules, several studies using the dihydroxyphen-
ylalanine (dopa) technique and/or electron microscopy have 
confirmed an increased number of melanocytes in these lesions 
[1,2,14- 16] . We refer to these macules as PUVA lent igines 
[1]. In contrast to ordinary lentigines induced by sunlight, 
PUV A lentigines may be comprised of melanocytes that are 
relatively hypertrophic and sometimes cytologically atypical 
[1,2,14,15,19]. 
Unlike dorsal hand lentigines [5- 8], which may be induced 
by sunlight or artificial sources of UVR, lentigines occurring 
on the buttocks of patients receiving chronic PUV A are likely 
to be therapy-induced. Data from the PUVA Follow-Up Study 
revealed that the overall frequency of buttock lentigines in -
creased significantly (from 45 % to 53%) when patients were 
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examined at an average of 3 years and then again at 5.7 years, 
respectively, after starting PUV A. The most significant factor 
associated with the frequency of buttock lentigines at the most 
recent examination (an average of 5.7 years after starting 
PUV A) was t he total number of PUV A treatments received. 
The significant associations of actinic damage and lentigines 
on the dorsa of the hands, and actinic damage on the buttocks, 
were presumed to be additional manifestations of a cumulative 
PUV A treatment effect. 
Although the number of PUV A treatments received was the 
most significant factor associated with the presence of buttock 
lentigines after chronic PUVA therapy, sex and age were also 
significantly associated, independent of a PUV A treatment 
effect. We cannot explain the slightly increased frequency of 
PUV A lentigines in men, nor the increased frequency among 
patients who started PUV A at age ~ 35 years. Both aging and 
UVR exposure have well-documented effects on human epider-
mal melanocytes. For instance, there is a 15% to 20% reduction 
in melanocyte density in both UVR-exposed and nonexposed 
human skin for each increment of 10 years between the ages of 
27 and 65 yea rs [22) . Despite this age-related reduction, how-
ever, dopa-reactive melanocytes consistently show a 2-fold 
greater density in UVR-exposed vs nonexposed human skin, 
and a doubling of density in response to experimental UVR 
exposure, regardless of age [22,23]. 
It is a commonly held notion that solar lentigines (senile 
lentigines, sen ile freckles) are more prevalent in older individ-
uals, presumably .the result of acute or chronic sun exposure 
[5- 8] . Such lesions have been observed in up to 75% of Cau-
casians aged 60 years and older (6). Grossly and microscopic-
ally, PUVA lentigines closely resemble solar lentigines [1]. 
Solar lentigines are acquired, circumscribed pigmented macules 
on sun-exposed skin, which consist of localized proliferations 
of melanocytes disposed predominantly about elongated epi-
dermal rete ridges [1,5- 8). Data from the PUVA Follow-Up 
Study revealed that before patients started PUV A, individuals 
aged 35 years and older were more likely to have had lentigines 
on the dorsa of the hands than individuals aged < 35 years 
(203/799, 25% vs 72/366, 20%) (p < 0.04). Presumably, len-
tigines on the dorsa of the hands before PUV A are the result of 
artificial sources of UVR other than PUV A, and/or solar irra-
diation. The significantly increased frequency of buttock len-
tigines among older patients receiving chronic PUV A may 
indicate a unique susceptibility of aging melanocytes to respond 
to UVR '' injury" by developing functionally active "fixed pro-
liferations." Alternatively, there may be unrecognized con-
founding variables that are responsible for this age-related 
effect. Further study is required to document age-related dif-
ferences in the induction of lentigines by PUV A and other 
sources of UVR. 
Konrad et al [15) experimentally produced "star-like hyper-
pigmented lentigines," which appeared 6- 8 months after mark-
edly phototoxic doses of PUVA. These lentigines were reported 
to show increased numbers of dopa-reactive melanocytes. Sim-
ilarly, Wilson and Kligman [21) demonstrated that 6-10 times 
the minimal erythema dose of UVB was required to induce 
circumscribed pigmented macules ("sunburn freck les") on the 
upper backs of human volunteers, and that a history of sun 
sensitivity and sun-induced "freckling" were permissive factors. 
In contrast to pigmented macules induced by PUVA, 2 speci-
mens of experimentally induced "sunburn freckles" prepared 
by Wilson and Kligman (21) using the split-dopa technique 
were reported to show " .. . no apparent increase in the number 
of melanocytes." Our own studies using split-skin preparations 
and vertical tissue sections incubated in dopa revealed that the 
former method is not as reliable as the latter for quantitative 
studies of melanocytes, especially for pigmented lesions char-
acterized by increased numbers of dopa-reactive melanocytes 
concentrated predominantly about elongated epidermal rete 
ridges and obscured by extensive melanin deposition in sur-
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rounding keratinocytes [1). Furthermore, we are not aware of 
proven gross morphologic criteria that can be used to reliably 
differentiate UVR-induced "freckles" [20,21) from UVR-in-
duced lentigines [1 ,5-8). We suspect that the vast majority of 
UVR-induced "freckles" represent an "injury response" to UVR 
and are, in fact, lentiginous proliferations of functionally active 
melanocytes [1] . 
In addition to sex, age, and the total number of PUV A 
treatments received, individual skin type was also significantly 
associated with the development of PUV A lentigines. After 
chronic PUV A therapy, patients with skin types V and VI were 
less likely to have moderate or extensive buttock lentigines 
than patients with skin types I- IV. This reduced risk, which 
could not be explained completely by a PUV A treatment effect, 
was presumed to be related to the "protective effect" of consti-
tutive pigmentation. (The smaller number of total treatments 
received by patients with skin type VI was probably related to 
the higher dropout rate for this subgroup, i.e., due to the relative 
ineffectiveness of PUV A for psoriasis in darkly pigmented 
individuals.) That patients with skin types V and VI do develop 
buttock lentigines if given sufficient PUVA treatment is illus-
trated by one of our patients with psoriasis and skin type VI , 
in whom pigmented macules appeared on the buttocks and 
penis, but on ly after a cumulative PUV A dose of 9614 joules/ 
cm2 given over the course of 7 years. The pigmented macules 
in this patient were documented to be lentigines by the dopa 
section technique (A. R. Rhodes, T. J. Harrist, and K. Momtaz-
T, unpublished observations). 
It is likely that patients with skin types V and VI have a 
reduced risk not only for PUV A lentigines, but for solar len-
tigines as well. This hypot hesis is supported by data from the 
PUV A- Follow-Up Study, which showed that the presence of 
moderate or extensive lentigines on the dorsa of the hands 
before PUV A therapy (i.e., related to UVR exposure other than 
PUVA) was highly dependent on skin type: type I, 44% (28/ 
64); type II, 27% (73/269); type III, 22 % (150/682); type IV, 
18% (27/151); and types V and VI, 5% (2/38) (p < 0.01). The 
significantly increased frequency of lentigines on the dorsa of 
the hands in patients with skin type I before starting PUV A, 
compared to the lack of a similar increase in frequency of 
buttoch lentigines in patients with the same skin type after 
chronic PUV A (Table I), could be ascribed to the usual method 
of adjusting PUV A dose based on the erythema response to 
therapy, i.e., patients with skin type I received a lower average 
PUV A dose than patients with skin types II- VI [3,4) (Table 
II). We suspect that skin type-related differences in the fre-
quency of lentigines on the dorsa of the hands before starting 
PUV A probably ref1ect "susceptibility" to equal doses of UVR 
energy more reliably than do skin type-related differences in 
the frequency of buttock lentigines after chronic PUV A ther-
apy, i.e. , UVR energy reaching the dorsa of the hands before 
starting PUV A (due to unregulated sun exposure, with or 
without UVB therapy) may be presumed to be more equally 
distributed for skin type than for UVR energy reaching the 
buttocks during chronic PUVA therapy. The interrelationships 
among UVR dose, UVR wavelength , skin type, and the devel-
opment of UVR-induced lentigines require additional study. 
The proliferations of hypertrophic and sometimes cytologi-
cally atypical melanocytes in PUV A-induced lentigines [1,2,14-
16,19) are similar to descriptions of sunlight-induced lentigines 
in patients with xeroderma pigmentosum [24). We note with 
concern, therefore, that PUVA-induced lentigines often per-
sisted for 1- 2 years (and longer) after PUVA was discontinued. 
We could not ascribe the persistence of buttock lentigines to 
"other" UVR therapy received after PUV A was discontinued, 
nor to the time interval from the last PUV A treatment to the 
most recent examination. The severity of buttock lentigines 
after PUV A was discontinued could be related almost entirely 
to a cumulative PUV A treatment effect. 
It will be important to examine the histology of PUV A-
Nov. 1983 
induced pigmented macules that remain long after PUV A is 
terminated. "Fixed" proliferations of atypical melanocytes may 
be potential foci for cutaneous melanoma [25,26]. Until addi-
tional information is available t hat will establish the clinical 
importance of PUV A lent igines, we recommend t hat patients 
who develop fixed pigmented lesions while receiving PUV A be 
monitored continually for atypical melanocytic proliferations, 
including melanoma. 
We wish to thank Drs. John A. Parrish a nd Thomas B. Fitzpatrick 
for encouraging us to conduct these studjes and for providing help fu l 
advice. Ms. Sa ndra Lania skillfully prepared the manuscript. 
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